NKNagalingeswaran KumarasamyMD, FRCP, PhDSlidesetHIVRSVAsia-Pacific HIV Clinical Forum 2022Therapeutic Options for Starting Antiretroviral Therapy - Nagalingeswaran Kumarasamy, MDView Slideset
TCTim CresseyMSc, PhDSlidesetHIVRSVAsia-Pacific HIV Clinical Forum 2022Pharmacological Considerations in Choice of Regimen - Tim Cressey, MSc, PhDView Slideset
LLLinghua LiMD, PhDSlidesetHIVRSVAsia-Pacific HIV Clinical Forum 2022Management of Major Comorbidity in the Region - Linghua Li, MD, PhDView Slideset
NPNicholas PatonMD, FRCPSlidesetHIVRSVAsia-Pacific HIV Clinical Forum 2022Constructing an Effective Treatment Regimen after ART Failure - Nicholas Paton, MD, FRCPView Slideset
SBSazali BasriMBBS, MMedSlidesetHIVRSVAsia-Pacific HIV Clinical Forum 2022Clinical Case (Focused on Treatment Switching) - Sazali Basri, MBBS, MMedView Slideset
JBJakkrapatara BoonruangMDSlidesetHIVRSVAsia-Pacific HIV Clinical Forum 2022Clinical Case (Focused on Prevention) - Jakkrapatara Boonruang, MDView Slideset
V(TViet (Mason) TrinhBScSlidesetHIVAsia-Pacific HIV Prevention Meeting 2022Con Standpoint of the Debate - Viet (Mason) Trinh, B.S.View Slideset
SlidesetHIVAsia-Pacific HIV Prevention Meeting 2022CON Perspective - Debate: When Available, Long-Acting Cabotegravir Should be the First Option for PrEP in Public Health Setting - Viet (Mason) TrinhView Slideset
GEGGlenda E. GrayMBBCH, FCPaeds (SA), DScSlidesetHIVAsia-Pacific HIV Prevention Meeting 2022Update on HIV Vaccine and Monoclonal AntibodyView Slideset
RSRobin SchaeferBA, MPH, PhDSlidesetHIVAsia-Pacific HIV Prevention Meeting 2022Long-Acting PrEP in Low- And Middle-Income CountriesView Slideset
AAAlejandro AfaniMDSlidesetHIVMexican HIV Clinical Forum 2022Initial Therapy. Two or Three Drugs - Alejandro AfaniView Slideset
NFNicole FinkelsteinSlidesetHIVMexican HIV Clinical Forum 2022PrEP - The Mexican Experience - Nicole FinkelsteinView Slideset
